Diagnosing Halogen Gas Exposure and Eosinophil-driven Diseases
Diagnosing Halogen Gas Exposure and Eosinophil-driven Diseases
Embedded Files
SLU ID 15-005 | Diagnostic biomarkers of leukocyte-mediated disease and halogen gas exposure
SLU ID 15-005 | Diagnostic biomarkers of leukocyte-mediated disease and halogen gas exposure
Intellectual Property Status
Intellectual Property Status
Seeking
Seeking
Patented
Know-how based
Licensee
Development partner
Commercial partner
Investment
University spin out
Background
Background
Currently, there are no biomarkers for halogen gas exposure. Additionally, there are no biomarkers for some eosinophil-driven diseases. Using biomarkers to identify the presence of disease avoids invasive surgical procedures to extract samples for pathology microscopic evaluation.
Overview
Overview
Researchers at Saint Louis University have developed a method of using glutathione adducts of 2-halofatty aldehydes (FALD-GSH) as an indicator of halogen gas exposure and pro-inflammatory leukocyte mediated disease.
Benefits
Benefits
The potential benefits of this technology include:
Minimizing the time required to diagnose halogen gas exposure and Eosinophil-driven diseases
Minimizing the complexity of diagnosing halogen gas exposure and Eosinophil-driven diseases
Minimizing the need for invasive diagnostic procedures
Applications
Applications
The potential applications of this technology include:
Diagnosing halogen gas exposure
Diagnosing Eosinophil-driven diseases
Opportunity
Opportunity
Saint Louis University is seeking a partner to further develop and commercialize this technology.
Report abuse